Novo Nordisk is testing oral semaglutide at weight-loss doses — a development of the Rybelsus (SNAC absorber) technology.
The same SNAC platform as Rybelsus, at obesity-program doses.
Clinical development; no obesity registration yet.
Confirms the trend: pharma solves the oral barrier point-by-point — the research peptide market stays injectable.
5/5 from 19 published reviews with photos (12 Nov 2026). All reviews with photos.
The page describes registered medicines/developments in a research context. We sell research materials only — not medicines.
No branded medicines. Research-class analogues are in the dated index.
🇻🇳 Dated index of 46 compounds · Telegram @vietpep · written before payment.